

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline Review, H2 2018

https://marketpublishers.com/r/I73623A7516EN.html

Date: September 2018 Pages: 74 Price: US\$ 2,000.00 (Single User License) ID: I73623A7516EN

Abstracts

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline Review, H2 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Interstitial Cystitis (Painful Bladder SyndromeBladder Pain Syndrome) - Pipeline Review, H2 2018, provides an overview of the Interstitial Cystitis (Painful Bladder SyndromeBladder Pain Syndrome) (Central Nervous System) pipeline landscape.

Interstitial cystitis also called painful bladder syndrome is a chronic condition in which person experience bladder pressure, bladder pain and sometimes pelvic pain, ranging from mild discomfort to severe pain. Symptoms include decreased bladder capacity, painful sexual intercourse, chronic pelvic pain and a persistent, urgent need to urinate. Risk factors include age, gender and chronic pain disorder, such as irritable bowel syndrome or fibromyalgia. Treatment includes non-steroidal anti-inflammatory drug, antidepressants and antihistamines.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Interstitial Cystitis (Painful Bladder SyndromeBladder Pain Syndrome) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Interstitial Cystitis (Painful Bladder SyndromeBladder Pain Syndrome) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the



descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Interstitial Cystitis (Painful Bladder SyndromeBladder Pain Syndrome) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 3, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Interstitial Cystitis (Painful Bladder SyndromeBladder Pain Syndrome) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Painful Bladder SyndromeBladder Pain Syndrome) (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Interstitial Cystitis (Painful Bladder SyndromeBladder Pain Syndrome) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.



The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Interstitial Cystitis (Painful Bladder SyndromeBladder Pain Syndrome) (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Interstitial Cystitis (Painful Bladder SyndromeBladder Pain Syndrome) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Interstitial Cystitis (Painful Bladder SyndromeBladder Pain Syndrome) (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Interstitial Cystitis (Painful Bladder SyndromeBladder Pain Syndrome) (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's



most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Interstitial Cystitis (Painful Bladder SyndromeBladder Pain Syndrome) (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contents

Introduction Global Markets Direct Report Coverage Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Overview Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Therapeutics **Development Pipeline Overview** Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Companies Involved in Therapeutics Development Astellas Pharma Inc Idera Pharmaceuticals Inc Kyorin Pharmaceutical Co Ltd **Kytogenics Pharmaceuticals Inc** Lipella Pharmaceuticals Inc UCB SA **Urigen Pharmaceuticals Inc** Xigen SA Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Drug Profiles Antisense Oligonucleotide to Inhibit NLRP3 for Interstitial Cystitis and Uveitis - Drug Profile **Product Description** Mechanism Of Action **R&D** Progress ASP-6294 - Drug Profile **Product Description** Mechanism Of Action **R&D** Progress brimapitide - Drug Profile



Product Description Mechanism Of Action **R&D** Progress certolizumab pegol - Drug Profile **Product Description** Mechanism Of Action **R&D** Progress dimethyl sulfoxide - Drug Profile **Product Description** Mechanism Of Action **R&D** Progress F-16357 - Drug Profile **Product Description** Mechanism Of Action **R&D** Progress GM-0111 - Drug Profile **Product Description** Mechanism Of Action **R&D** Progress lidocaine - Drug Profile **Product Description** Mechanism Of Action **R&D** Progress LP-08 - Drug Profile **Product Description** Mechanism Of Action **R&D** Progress mesalamine - Drug Profile **Product Description** Mechanism Of Action **R&D** Progress NEO-5937 - Drug Profile **Product Description** Mechanism Of Action **R&D** Progress onabotulinumtoxinA - Drug Profile **Product Description** Mechanism Of Action R&D Progress



pentosan polysulfate sodium - Drug Profile **Product Description** Mechanism Of Action R&D Progress Stem Cell Therapy for Interstitial Cystitis and Metabolic Disorders - Drug Profile **Product Description** Mechanism Of Action **R&D** Progress URG-801 - Drug Profile **Product Description** Mechanism Of Action **R&D** Progress Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Dormant Projects Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Discontinued Products Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Product **Development Milestones** Featured News & Press Releases Sep 27, 2016: Idera Pharmaceuticals Presents New Third Generation Antisense (3GA) Data at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis Appendix Methodology Coverage Secondary Research **Primary Research Expert Panel Validation** Contact Us Disclaimer



List Of Tables

LIST OF TABLES

Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), H2 2018 Number of Products under Development by Companies, H2 2018 Number of Products under Development by Universities/Institutes, H2 2018 Products under Development by Companies, H2 2018 Products under Development by Universities/Institutes, H2 2018 Number of Products by Stage and Target, H2 2018 Number of Products by Stage and Mechanism of Action, H2 2018 Number of Products by Stage and Route of Administration, H2 2018 Number of Products by Stage and Molecule Type, H2 2018 Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Astellas Pharma Inc, H2 2018 Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Idera Pharmaceuticals Inc, H2 2018 Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018 Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Kytogenics Pharmaceuticals Inc, H2 2018 Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Lipella Pharmaceuticals Inc, H2 2018 Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by UCB SA, H2 2018 Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Urigen Pharmaceuticals Inc, H2 2018 Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Xigen SA, H2 2018 Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Dormant Projects, H2 2018 Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Discontinued Products, H2 2018



List Of Figures

LIST OF FIGURES

Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), H2 2018 Number of Products under Development by Companies, H2 2018 Number of Products by Top 10 Targets, H2 2018 Number of Products by Stage and Top 10 Targets, H2 2018 Number of Products by Top 10 Mechanism of Actions, H2 2018 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 Number of Products by Routes of Administration, H2 2018 Number of Products by Stage and Routes of Administration, H2 2018 Number of Products by Stage and Routes of Administration, H2 2018 Number of Products by Molecule Types, H2 2018 Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Astellas Pharma Inc Idera Pharmaceuticals Inc Kyorin Pharmaceutical Co Ltd Kytogenics Pharmaceuticals Inc Lipella Pharmaceuticals Inc UCB SA Urigen Pharmaceuticals Inc Xigen SA



I would like to order

Product name: Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline Review, H2 2018

Product link: https://marketpublishers.com/r/I73623A7516EN.html

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/I73623A7516EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline Review, H2 2018